EQL Pharma AB (FRA:7JK) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7JK EQL Pharma AB FRA:7JK
58 GF Score
Price €2.00
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:7JK
58GF Score
EQL Pharma AB FRA:7JK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Business Description

Other Exchanges EQL:Sweden7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
58GF Score

Get the complete analysis for FRA:7JK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price